Ruprecht-Karls-Universitaet Heidelberg

Deutsches Krebsforschungszentrum

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Ruprecht-Karls-Universitat Heidelberg

Universitaetsklinikum Heidelberg

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Universitatsklinikum Heidelberg

Zahari Raykov

Jean Rommelaere

Marc Aprahamian

Nathalia Giese

Karsten Geletneky

Laurent Daeffler

Irina Kiprijanova

Svitlana Grekova

Joerg Schlehofer

Assia Angelova

Tanja Heimberger

Jörg Schlehofer

Celina Czeipluch

Markus Buechler

Jens Werner

Ute Koch

Thomas Giese

Celina Cziepluch

Laurent DÄFFLER

Laurent Daffler

Markus Buchler

Markus Büchler

A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma.

Parovirus having a CpG-enriched genome useful for cancer therapy

The present invention relates to a combination of a parvovirus and a cytokine, preferably IFN, for use in treating pancreatic cancer, in particular a terminal stage of this disease.

Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer

Described is a parvovirus for preventing recurrence of a tumor, preferably a malignant brain tumor or pancreas tumor.

Oncolytic virotherapy for prevention of tumor recurrence

Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.

Methods of treating cancer using chemovirotherapy

Parvovirus having a CPG-enriched genome useful for cancer therapy

Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine.

Parvovirus cancer therapy and combination with chemotherapy

Growing community of inventors

Heidelberg, Germany

Zahari Raykov